Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Myriad Genetics Inc (NASDAQ:MYGN)

31.97
Delayed Data
As of Jul 22
 -0.24 / -0.75%
Today’s Change
28.82
Today|||52-Week Range
46.24
-25.93%
Year-to-Date
Here's Why Myriad Genetics Is Down 26% in 2016
Jul 21 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close32.21
Today’s open32.24
Day’s range31.84 - 32.41
Volume652,509
Average volume (3 months)912,888
Market cap$2.2B
Dividend yield--
Data as of 3:59pm ET, 07/22/2016

Growth & Valuation

Earnings growth (last year)-52.00%
Earnings growth (this year)+13.41%
Earnings growth (next 5 years)+14.05%
Revenue growth (last year)-7.08%
P/E ratio21.6
Price/Sales3.50
Price/Book3.33

Competitors

 Today’s
change
Today’s
% change
IPXLImpax Laboratories I...-0.09-0.29%
MDCOMedicines Co+0.30+0.86%
GLPGGalapagos NV+0.17+0.32%
GWPHGW Pharmaceuticals P...+0.93+0.99%
Data as of 3:59pm ET, 07/22/2016

Financials

Next reporting dateAugust 9, 2016
EPS forecast (this quarter)$0.37
Annual revenue (last year)$723.1M
Annual profit (last year)$80.2M
Net profit margin11.09%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark C. Capone
Executive Vice President-
International Operations
Gary A. King
Corporate headquarters
Salt Lake City, Utah

Forecasts

Partner Offers

Search for Jobs